Drug Profile
Interleukin-12 - Ichor Medical Systems
Alternative Names: IL-12/TriGrid™ - Ichor Medical SystemsLatest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator Ichor Medical Systems
- Class Adjuvants; Immunotherapies; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 12 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 22 Jun 2005 This compound is still in active development for Cancer
- 15 Sep 2003 Preclinical trials in Cancer in USA (Intratumoural)